News
The regulator’s priority review and sBLA approval of the antibody were supported by data from Phase III and Phase II trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback